SANDOZ CEFTRIAXONE POWDER FOR SOLUTION

Krajina: Kanada

Jazyk: angličtina

Zdroj: Health Canada

Aktívna zložka:

CEFTRIAXONE (CEFTRIAXONE SODIUM)

Dostupné z:

SANDOZ CANADA INCORPORATED

ATC kód:

J01DD04

INN (Medzinárodný Name):

CEFTRIAXONE

Dávkovanie:

1G

Forma lieku:

POWDER FOR SOLUTION

Zloženie:

CEFTRIAXONE (CEFTRIAXONE SODIUM) 1G

Spôsob podávania:

INTRAMUSCULAR

Počet v balení:

100

Typ predpisu:

Prescription

Terapeutické oblasti:

THIRD GENERATION CEPHALOSPORINS

Prehľad produktov:

Active ingredient group (AIG) number: 0117292003; AHFS:

Stav Autorizácia:

CANCELLED PRE MARKET

Dátum Autorizácia:

2018-08-01

Súhrn charakteristických

_ _
PRODUCT MONOGRAPH
SANDOZ CEFTRIAXONE
Sterile Ceftriaxone for Injection BP
1 G AND 2 G CEFTRIAXONE PER VIAL (INCORPORATED AS CEFTRIAXONE SODIUM)
ANTIBIOTIC
Sandoz Canada Inc.
Date of Revision: January 15, 2010
145 Jules-Léger
Boucherville, QC, Canada
J4B 7K8
CONTROL # : 133307
_Sandoz Ceftriaxone _
_ Page 2 of 51_
_ _
TABLE OF CONTENTS
HEALTH PROFESSIONAL
INFORMATION.........................................................................
3
ACTION
.....................................................................................................................................
3
INDICATIONS AND CLINICAL
USES...................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
4
WARNINGS...............................................................................................................................
4
PRECAUTIONS.........................................................................................................................
6
ADVERSE
REACTIONS...........................................................................................................
8
SYMPTOMS AND TREATMENT OF OVERDOSAGE
....................................................... 10
DOSAGE AND
ADMINISTRATION.....................................................................................
10
ADMINISTRATION................................................................................................................
11
PHARMACEUTICAL
INFORMATION.................................................................................
13
DRUG
SUBSTANCE...............................................................................................................
13
DRUG
PRODUCT....................................................................................................................
13
RECONSTITUTION
.......................................................................................